FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2223373329> ?p ?o ?g. }

• W2223373329 endingPage "5120" @default.
• W2223373329 startingPage "5120" @default.
• W2223373329 abstract "5120 Background: A Phase 1 trial is underway to study the GM-CSF-secreting immunotherapy for prostate cancer (GVAX immunotherapy [GVAX IT]) and ipilimumab (ipi) in mHRPC patients (pts). Methods: Twelve pts were treated for 24 weeks (wks) with bi-weekly intradermal injections of GVAX IT and monthly Ipi. Pts were enrolled in cohorts of 3; each cohort received an escalating dose of ipi: 0.3, 1, 3 or 5 mg/kg. Results: Median follow-up is 15.0 months. All pts had GVAX IT injection site reactions. Five of six pts at the higher ipi doses (3 and 5 mg/kg) developed Grade 2 or 3 immune-related endocrinopathy, consistent with hypophysitis manifested by adrenal insufficiency and/or hypothyroidism, all successfully treated with standard hormone replacement. Two pts were tapered off Synthroid within 6 months (m). There was no induction of the alpha-21-hydroxylase auto-antibody that is seen in 90% of cases of auto-immune adrenal insufficiency. One pt in the 5 mg group developed a Grade 3 dose-limiting alveolitis. PSA responses (declines > 50%) were seen in 5/6 treated at the two higher ipi doses with median response duration of 4.9 m (2 on-going at 7.2 m and 12.8 m). These PSA responses were associated with immune-related endocrinopathy but were not consistently correlated with declines in adrenal androgens. One pt had resolution of measurable disease on abdominal CT scan. Immunomonitoring studies showed T cell and dendritic cell activation, more pronounced at higher doses. Biopsies of injection sites showed T cell infiltration. Multiple tumor-reactive antibodies (abs) induced by tx were identified by serologic analysis (SEREX), including abs to filamin B. Screening against 20 defined prostate cancer antigens demonstrated induction of abs to PSMA and NY-ESO-1. Conclusions: The GVAX IT and ipilimumab combination is active in mHRPC. There was an association between PSA response and immune-related adverse events. The PSA responses cannot be accounted for by adrenal insufficiency. The relationship between clinical activity and serologic response to identified antigens is under investigation. Tx of 16 additional pts is planned. No significant financial relationships to disclose." @default.
• W2223373329 created "2016-06-24" @default.
• W2223373329 creator A5029806136 @default.
• W2223373329 creator A5031475492 @default.
• W2223373329 creator A5053105927 @default.
• W2223373329 creator A5053138681 @default.
• W2223373329 creator A5057555103 @default.
• W2223373329 creator A5066911227 @default.
• W2223373329 creator A5070095269 @default.
• W2223373329 creator A5072294716 @default.
• W2223373329 creator A5088308326 @default.
• W2223373329 creator A5091886021 @default.
• W2223373329 date "2007-06-20" @default.
• W2223373329 modified "2023-10-17" @default.
• W2223373329 title "Biochemical and immunologic correlates of clinical response in a combination trial of the GM-CSF-gene transduced allogeneic prostate cancer immunotherapy and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHRPC)" @default.
• W2223373329 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.5120" @default.
• W2223373329 hasPublicationYear "2007" @default.
• W2223373329 type Work @default.
• W2223373329 sameAs 2223373329 @default.
• W2223373329 citedByCount "9" @default.
• W2223373329 countsByYear W22233733292014 @default.
• W2223373329 crossrefType "journal-article" @default.
• W2223373329 hasAuthorship W2223373329A5029806136 @default.
• W2223373329 hasAuthorship W2223373329A5031475492 @default.
• W2223373329 hasAuthorship W2223373329A5053105927 @default.
• W2223373329 hasAuthorship W2223373329A5053138681 @default.
• W2223373329 hasAuthorship W2223373329A5057555103 @default.
• W2223373329 hasAuthorship W2223373329A5066911227 @default.
• W2223373329 hasAuthorship W2223373329A5070095269 @default.
• W2223373329 hasAuthorship W2223373329A5072294716 @default.
• W2223373329 hasAuthorship W2223373329A5088308326 @default.
• W2223373329 hasAuthorship W2223373329A5091886021 @default.
• W2223373329 hasConcept C121608353 @default.
• W2223373329 hasConcept C126322002 @default.
• W2223373329 hasConcept C143998085 @default.
• W2223373329 hasConcept C203014093 @default.
• W2223373329 hasConcept C2777701055 @default.
• W2223373329 hasConcept C2780192828 @default.
• W2223373329 hasConcept C2781433595 @default.
• W2223373329 hasConcept C71924100 @default.
• W2223373329 hasConcept C8891405 @default.
• W2223373329 hasConcept C90924648 @default.
• W2223373329 hasConceptScore W2223373329C121608353 @default.
• W2223373329 hasConceptScore W2223373329C126322002 @default.
• W2223373329 hasConceptScore W2223373329C143998085 @default.
• W2223373329 hasConceptScore W2223373329C203014093 @default.
• W2223373329 hasConceptScore W2223373329C2777701055 @default.
• W2223373329 hasConceptScore W2223373329C2780192828 @default.
• W2223373329 hasConceptScore W2223373329C2781433595 @default.
• W2223373329 hasConceptScore W2223373329C71924100 @default.
• W2223373329 hasConceptScore W2223373329C8891405 @default.
• W2223373329 hasConceptScore W2223373329C90924648 @default.
• W2223373329 hasIssue "18_suppl" @default.
• W2223373329 hasLocation W22233733291 @default.
• W2223373329 hasOpenAccess W2223373329 @default.
• W2223373329 hasPrimaryLocation W22233733291 @default.
• W2223373329 hasRelatedWork W1572810235 @default.
• W2223373329 hasRelatedWork W1598282186 @default.
• W2223373329 hasRelatedWork W1967568184 @default.
• W2223373329 hasRelatedWork W2003086854 @default.
• W2223373329 hasRelatedWork W2005748678 @default.
• W2223373329 hasRelatedWork W2027015554 @default.
• W2223373329 hasRelatedWork W2064686787 @default.
• W2223373329 hasRelatedWork W2071315909 @default.
• W2223373329 hasRelatedWork W2126688981 @default.
• W2223373329 hasRelatedWork W51843423 @default.
• W2223373329 hasVolume "25" @default.
• W2223373329 isParatext "false" @default.
• W2223373329 isRetracted "false" @default.
• W2223373329 magId "2223373329" @default.
• W2223373329 workType "article" @default.